20. October 2022
Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy
Read more | Document
20. October 2022
Kooperations- und Lizenzvereinbarung zwischen Takeda, Zedira und Dr. Falk Pharma zur Entwicklung einer First-in-Class-Therapie für die Zöliakie
Read more | Document
19. October 2022
Co-authored posters at ICDS 2022
Read more | Document
15. September 2022
Successful ISO9001:2015 recertification
Read more | Document
1. July 2022
Dr. Falk Pharma und Zedira geben den Beginn einer Phase-2a-Wirksamkeitsstudie für ZED1227 zur Behandlung nicht-alkoholischer Fettlebererkrankung (NAFLD) bekannt
Read more | Document
1. July 2022
Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
Read more | Document
20. May 2022
Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
Read more | Document
11. April 2022
Zedira supports Gordon Research Seminar
Read more | Document

News

Blog

Events